Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP)
about
sameAs
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Impact of a critical pathway on acute myocardial infarction quality indicatorsImpact of a cardiac risk reduction program in vulnerable patients hospitalized with coronary artery diseaseMedications for the treatment of acute coronary syndromesImproving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiativeDiagnosis and treatment of peripheral arterial disease compared with other atherosclerotic vascular diseases in a university primary care clinicImplementation of case management to reduce cardiovascular disease risk in the Stanford and San Mateo Heart to Heart randomized controlled trial: study protocol and baseline characteristicsA new paradigm of cardiovascular risk factor modificationA novel family-based intervention trial to improve heart health: FIT Heart: results of a randomized controlled trial.A randomized clinical trial of secondary prevention among women hospitalized with coronary heart diseaseDepression and poor adherence to lipid-lowering medications among patients with coronary artery diseaseStandardised pre-hospital care of acute myocardial infarction patients: MISSION! guidelines applied in practice.Benefits of statin therapy and compliance in high risk cardiovascular patients.Initiation of treatment for incident diabetes: evidence from the electronic health records in an ambulatory care settingThe reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarctionLong-term outcomes of regional variations in intensity of invasive vs medical management of Medicare Patients with acute myocardial infarction.Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initThe importance of lipid evaluation and management in the prevention and treatment of acute myocardial infarction.The new cholesterol guidelines. Applying them in clinical practice.An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement programTemporal trends of system of care for STEMI: insights from the Jakarta Cardiovascular Care Unit Network System.The importance of in-hospital statin therapy for patients with acute coronary syndromes.Behavior matters.Role of the pharmacist in establishing lipid intervention programs.Recognition of incident diabetes mellitus during an acute myocardial infarctionAdherence to statin treatment following a myocardial infarction: an Italian population-based survey.Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set.Lessons from the management of chronic heart failure.The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia.Should standard medical therapy for angina include a statin?Cardiovascular risk in survivors of stroke.Present and future of secondary prevention after an acute coronary syndrome.The electronic health record--the time is now.Lipid-lowering therapy for elderly patients at risk for coronary events and stroke.Assessment of compliance with lipid guidelines in an academic medical center.Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up.Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery.Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD.
P2860
Q24794251-51EB7830-8E45-4B70-BC34-358E0B84325FQ24796000-70526DC0-CEA6-41CC-B835-E2CFC39F232AQ28167564-01922125-066C-466E-A51A-B233166E5F31Q28169132-BB2DBDC0-5AFF-462B-AE5F-171D5258CC79Q28193674-67239512-7793-41FA-BF23-F9A681E9A7ABQ28194111-3FF95C30-96EA-4B94-A111-269326E17719Q28200505-14D97352-0DB6-4BD7-9A66-4FEB24960A2DQ28200558-70BAE720-A9BC-4722-BBF2-ECB6A63B714AQ28219234-8BB493D7-9871-44B0-985F-BD70F2684DFEQ33572497-9180B479-3F85-4D98-972E-A07669D44085Q33829406-16D9EC2E-3739-4B57-A902-665FE3D8373FQ34056729-809C379C-7E00-423F-B71F-1520D3245279Q34135254-25E16683-09FB-49EA-BCBD-88E7D6A7EDEAQ34187551-6DCBA980-EDD3-49C6-A3E1-90080E20E319Q34459227-86D9778A-CA4D-40FF-88AA-8F6AA5D6880EQ34564126-EB431F67-B9C7-4C75-9F0E-33326935EDA0Q34599841-F41D18A8-F05E-4164-9A4A-9A6275A78A78Q34683098-005391A9-D42C-4509-AB4B-20BDE9BCA021Q34714717-E8485C76-9D01-4505-95B2-42403A745292Q34800158-6027146C-EC98-4811-BC22-0CA15BB3C53CQ34911839-3357B499-9C6A-4F64-99C6-C2A70C167F0DQ35092590-93C7970B-62EC-4388-9FAB-84C99969DB3BQ35101478-434D839B-27E3-4BA7-BD20-7485E49636E2Q35109924-F34DD57F-4849-49F7-9629-B87626AFE2FDQ35549743-B251FF19-2365-4ECF-9C3B-68980B196E02Q35629691-F7BC11E3-124C-43F9-8192-DBB7BC3891B7Q35687652-2A17E61A-C56C-4D96-86FE-A5F28537BBB5Q35743179-CA9BEDF5-A7B1-4DFA-9A6C-4E24E520C6FFQ35808265-103563E7-B1F2-4CF5-B9C0-06C5E7B12429Q35843906-FFEA011E-E4C9-42D7-AEB1-EEA262854D01Q35875455-35B8B8B7-07E2-4719-A13A-7E6C91E601CCQ35955693-36464C65-6BFA-4304-A33D-F54CE478B8C7Q35968346-AD563E17-1E10-434B-9469-0D0F3CD7F741Q36118008-9D6045EA-6D55-4E6A-BE08-F07E7B3C30C4Q36232827-BEF6668B-2B2B-4E9D-9B0F-E4A2AD82BCE9Q36332237-43709918-6BF0-48D0-8C33-84442FCCD882Q36341258-FD05EEFB-F750-4394-9756-020B229F0845Q36360311-E97856C2-E216-48A0-A1BE-36C39421E5CFQ36402654-F707D5CC-0E4C-405A-9613-B52BCDA49655Q36428054-993F31FC-92F4-4EFA-B8DB-5B5EECCB73F9
P2860
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP)
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Improved treatment of coronary ...... sis Management Program (CHAMP)
@ast
Improved treatment of coronary ...... sis Management Program (CHAMP)
@en
Improved treatment of coronary ...... sis Management Program (CHAMP)
@nl
type
label
Improved treatment of coronary ...... sis Management Program (CHAMP)
@ast
Improved treatment of coronary ...... sis Management Program (CHAMP)
@en
Improved treatment of coronary ...... sis Management Program (CHAMP)
@nl
prefLabel
Improved treatment of coronary ...... sis Management Program (CHAMP)
@ast
Improved treatment of coronary ...... sis Management Program (CHAMP)
@en
Improved treatment of coronary ...... sis Management Program (CHAMP)
@nl
P2093
P3181
P1476
Improved treatment of coronary ...... sis Management Program (CHAMP)
@en
P2093
A Gawlinski
G C Fonarow
J H Tillisch
S Moughrabi
P304
P3181
P356
10.1016/S0002-9149(00)01519-8
P407
P577
2001-04-01T00:00:00Z